3 Needs context
Oliver Smithies and Mario Capecchi received the Nobel Prize for homologous recombination decades before Jennifer Doudna and Emmanuelle Charpentier won for CRISPR.
"notably homologous recombination, which Smithies and Capecchi got the Nobel Prize for decades before Jennifer and Emmanuelle." (said at 0:38:27)
Mario Capecchi and Oliver Smithies (along with Sir Martin J. Evans) were awarded the Nobel Prize in Physiology or Medicine in 2007 for their development of gene targeting in embryonic stem cells using homologous recombination. Jennifer Doudna and Emmanuelle Charpentier received the Nobel Prize in Chemistry in 2020 for the development of CRISPR/Cas9 genome editing. While the foundational discoveries of homologous recombination in mammalian cells took place in the 1980s (several decades prior to Doudna and Charpentier's 2012 CRISPR work), the Nobel Prizes themselves were awarded 13 years apart (2007 vs. 2020), rather than multiple decades apart.
Follistatin and TERT gene therapy treatments produced a statistically significant longevity extension in rodents.
"In the case of the follistatin and TERT treatments, those did show a pretty significant, very significant longevity effect on the rodents." (said at 1:06:30)
The speaker refers to rodent gene therapy studies testing telomerase reverse transcriptase (TERT) and follistatin (FST). A 2022 study in PNAS reported that mouse cytomegalovirus vectors delivering TERT or follistatin extended median lifespan in mice by 41.4% and 32.5%, respectively; however, that publication was retracted in 2025. An earlier 2012 study demonstrated that adeno-associated virus (AAV)-mediated TERT gene therapy extended median lifespan by 13% to 24% in adult and old mice. Because the key study evaluating follistatin alongside TERT was retracted, and remaining evidence is limited strictly to rodent models, the evidence for these treatments is of very low certainty and requires qualification.
The human Lyme disease vaccine was withdrawn from the market following controversy associated with Andrew Wakefield's fraudulent claims linking vaccines to autism.
"There also is, you know, there is a pretty good Lyme vaccine that was blocked for no particularly great reason. It was, uh, it happened to bad timing that happened around the same time as the fake data on, uh, uh, vaccines causing autism. Wakefield, I think, was this scientist's name who who faked the data, and later was when that was revealed, but the damage was already done. People kept repeating it as if for a fact for many years after it was shown to be false. Um, and so they pulled the the, um, Lyme disease vaccine off." (said at 1:46:36)
The human Lyme disease vaccine (LYMErix, an OspA-based vaccine) was approved by the FDA in 1998 and voluntarily withdrawn by manufacturer GlaxoSmithKline in 2002 due to plummeting consumer demand, media sensationalism, and class-action lawsuits. While this coincided temporally with the broader surge in anti-vaccine sentiment following Andrew Wakefield's fraudulent 1998 paper on the MMR vaccine and autism, the specific controversy that doomed LYMErix centered on unproven allegations that the vaccine triggered autoimmune arthritis via molecular mimicry, not autism. Subsequent post-marketing surveillance and FDA reviews found no statistically significant increase in arthritis among vaccine recipients compared to unvaccinated controls, confirming the vaccine was safe and effective, but public confidence had collapsed.
42 Supported by research
The Human Genome Project began as a $3 billion project to sequence a single reference genome for humans.
"The Human Genome Project began as a $3 billion moonshot shortly after Dr. Church first pioneered a method of direct DNA sequencing in 1984, the goal to sequence a single reference genome for humans." (said at 0:01:03)
The Human Genome Project (HGP) was formally launched in 1990 with an estimated budget of approximately $3 billion (planned at roughly $1 per base pair for the 3-billion-base human genome over a projected 15-year timeline) to generate a high-quality reference sequence of the human genome. Initial discussions and technical foundations began in the mid-1980s following key technological advances in DNA sequencing, including direct genomic sequencing methods introduced in 1984.
DNA sequencing has become over 10-million-fold cheaper compared to when direct sequencing was first pioneered.
"Sequencing is now over 10-million-fold cheaper, and most people can get their genome sequenced inexpensively if they so desire." (said at 0:01:20)
The cost of DNA sequencing has dropped by more than 10-million-fold since direct DNA sequencing methodologies (such as Sanger dideoxy sequencing and Maxam-Gilbert chemical cleavage) were first pioneered in the late 1970s. The original Human Genome Project required billions of dollars, and early capillary sequencing runs cost tens to hundreds of millions of dollars per human genome (for example, approximately $100 million at Celera Genomics in 2000–2001). With the advent and maturation of massively parallel high-throughput sequencing technologies, whole-genome sequencing costs have dropped to well under $1,000 per genome, representing a reduction factor exceeding ten million compared to early direct sequencing.
- context: Overview of DNA Sequencing Strategies (Current Protocols in Molecular Biology 2011) · cited 131x in the literature
"Efficient and cost-effective DNA sequencing technologies are critical to the progress of molecular biology. This overview of DNA sequencing strategies provides a high-level review of seven distinct approaches to DNA sequencing... The primary focus here is on Sanger dideoxy sequencing, which has been the dominant technology since 1977, and on cyclic array strategies, for which several competitive implementations have been developed since 2005." (abstract, passage verified)
openalexfull study (doi) - supports: The Sequence of the Human Genome (Clinical Chemistry 2015) · cited 1654x in the literature
"In contrast to our approach with WGS, the federal Human Genome Project was conceived as a 15-year, $3 billion project that settled on a clone-by-clone sequencing approach... To reconstruct the human sequence at Celera, we took advantage of 350 new capillary DNA sequencing machines. The machines could be run in a single production environment to generate 25 million sequence reads of around 600 bp each over a 9-month period for a cost of approximately $100 million." (abstract, main text)
openalexfull study (doi)
Walter Gilbert's team and Fred Sanger independently published DNA sequencing methods in 1977.
"and then Wally Gilbert was my mentor as a graduate student, and his team in 1977—independently, Fred Sanger published a paper that same year." (said at 0:03:20)
Walter Gilbert (with Allan Maxam) and Frederick Sanger (with Steve Nicklen and Alan R. Coulson) independently developed and published revolutionary DNA sequencing methods in 1977. Maxam and Gilbert published their chemical cleavage sequencing method, while Sanger and colleagues published the chain-termination (dideoxy) sequencing method that same year.
The United States component of the Human Genome Project was divided into approximately 30% Department of Energy and 70% NIH funding starting in 1990 with a 15-year goal.
"And they did it kind of in teamwork with maybe 30% DOE and 70% NIH in the United States component, plus lots of international collaboration, really starting in 1990 with a 15-year goal." (said at 0:04:28)
Historical documentation of the Human Genome Project confirms that the United States effort officially began in 1990 as a coordinated partnership between the National Institutes of Health (NIH) and the Department of Energy (DOE) with an initial 15-year timeline targeted for completion by 2005. The US funding allocation across the two participating agencies closely followed a ~70% NIH to ~30% DOE division of budgetary resources alongside substantial international collaboration.
- supports: The Human Genome Project (Humana Press eBooks 1998)
"The Human Genome Project (HGP) was conceived in the mid-1980s as an ambitious effort to characterize the human genome, ultimately culminating with a complete DNA sequence by the year 2005. The accomplishment of this goal would locate the ~80,000 genes and provide the DNA sequence (~3 × 10 9 bp) for the entire genome at an estimated cost of $3 billion over 15 years. The project has evolved as an international effort, driven forward by numerous scientific groups and funding agencies. Exchange of information and biological materials has been facilitated by the Human Genome Organization (HUGO). In the United States, the genome project was officially launched in 1990 by the National Institutes of Health (NIH) and the Department of Energy (DOE)." (abstract, main text, passage verified)
openalexfull study (doi)
The completed draft of the Human Genome Project covered approximately 92% of the genome.
"So a lot of these shortcuts were really ill-conceived, but fortunately, we did get a decent 92% of the genome and declared victory." (said at 0:05:43)
The speaker's statement is supported by published genomic literature. Although the Human Genome Project announced completion after resolving approximately 99% of the euchromatic portion of the human genome, approximately 8% of the total genome remained unfinished or unsequenced (chiefly heterochromatin, centromeres, and repetitive regions), giving roughly 92% coverage of the total genome until the Telomere-to-Telomere consortium completed the remaining 8% in the T2T-CHM13 assembly.
Church's lab has achieved up to 24,000 edits in a single genome using enzymatic targeting methods.
"The maximum number of edits we've done by editing, meaning having an enzyme that's targeted to a particular place, is 24,000." (said at 0:19:22)
The claim is supported by published research from George Church's laboratory. Using targeted enzymatic methods (specifically Cas-derived base editors targeting repetitive retrotransposon sequences without causing lethal DNA double-strand breaks), the group demonstrated large-scale multiplex editing reaching up to tens of thousands of loci per cell (including ~13,200 in 293T cells, ~12,200 in human induced pluripotent stem cells, and up to ~24,000 retrotransposon loci edited across experimental conditions).
Reintroducing wolves to Yellowstone National Park after 70 years altered large herbivore abundance, willow and tree growth, and beaver behavior.
"The most famous one is probably restoring the wolves to Yellowstone after 70 years. It had a typical keystone effect, had a ripple effect that was anticipated and worked out, which was they changed the abundance of large herbivores, which then changed the abundance of the willows and other trees, which changed the beavers' behavior, which built lakes, which resulted in aquaculture." (said at 0:23:20)
Ecological studies monitoring Yellowstone National Park following the 1995–1996 reintroduction of gray wolves (after an approximate 70-year absence) document a classic top-down trophic cascade. Wolf predation and behavioral displacement reduced Rocky Mountain elk density and browsing pressure, allowing riparian woody vegetation—notably willows and aspen—to recover substantially in height and biomass. This vegetation recovery facilitated an increase in beaver colonies and dam-building activity across riparian corridors, though researchers note that multicausal factors (including bison population dynamics, hydrological changes, and climate) also influence the pace and spatial variation of ecosystem recovery.
- supports: The History and Current Status and Distribution of Beavers in Yellowstone National Park (Northwest Science 2012) · cited 28x in the literature
"In 1996, 1998, 1999, 2001, 2003, 2005, 2007 and 2009 complete, park-wide aerial surveys were conducted and active colonies ranged from 44 (1996) to 127 (2007) with an increasing trend. Therefore, in a period of about 90 years (1920s—2000s) the beaver population in the northern portion of the park appears to have declined then increased probably because of a willow recovery." (abstract, results, passage verified)
openalexfull study (doi) - supports: Tall willow thickets return to northern Yellowstone (Ecosphere 2020) · cited 11x in the literature
"Following large carnivore restoration in the late 1990s, elk numbers decreased, and some researchers reported willows growing taller with reductions in browsing, evidence of a shift toward willow recovery... Our results demonstrate that the reduction of elk herbivory over the last two decades in northern Yellowstone has allowed willows to grow taller in many places, despite a warming and drying climate, while increased herbivory by bison continues to suppress willows in some locations." (abstract, results, passage verified)
openalexfull study (doi) - supports: The strength of the Yellowstone trophic cascade after wolf reintroduction (Global Ecology and Conservation 2025) · cited 22x in the literature
"Reduced herbivory pressure from Rocky Mountain elk ( Cervus canadensis ) followed their reintroduction, leading to increased growth in willows. Crown volume, a proxy for above-ground biomass, was calculated using a predictive model based on willow height and was used to index primary producer response. Data from a 20-year study (2001–2020) revealed a relatively strong trophic cascade, with a ∼1500 % increase in average willow crown volume and a log 10 ratio of 1.21." (abstract, results, passage verified)
openalexfull study (doi)
Replacing the active site serine's hydroxyl oxygen with a hydrogen turns the residue into alanine and renders a serine protease completely functionless without altering its 3D structure.
"let's say you take a serine protease. It's called a serine protease because there's a very key serine right at the active site, and that serine has an oxygen that's part of the mechanism. If you change that oxygen, that hydroxyl to a hydrogen, it now becomes an alanine and it's completely functionless. But the three-dimensional structure is completely preserved." (said at 0:26:40)
The speaker accurately describes the biochemical definition and experimental manipulation of serine proteases. Chemically, serine possesses a hydroxymethyl side chain (-CH2OH); replacing the hydroxyl group (-OH) with a hydrogen atom (-H) yields a methyl group (-CH3), which is alanine. Mutating the catalytic serine residue to alanine (such as S195A in trypsin/chymotrypsin or S221A in subtilisin) abolishes the nucleophile necessary for peptide bond cleavage, reducing catalytic efficiency by millions-fold (rendering it proteolytically inactive) while preserving the native overall three-dimensional fold and substrate-binding geometry. This property is widely used in structural biology to crystallize stable enzyme-substrate or enzyme-inhibitor complexes.
All known viruses rely on the host cell's genetic code and ribosomal translation machinery.
"The way that it works is that all viruses, as far as we know, depend on the host genetic code, the translation ribosomal machinery." (said at 0:16:20)
The claim accurately reflects a foundational principle of virology and molecular biology. Because viruses lack ribosomes and the enzymatic machinery necessary to synthesize proteins independently, all known viruses are obligate intracellular parasites that completely depend on the host cell's translation apparatus, ribosomes, and standard genetic decoding machinery to translate their viral mRNA into viral proteins.
In the standard genetic code, there are 64 triplet codons, and AAA codes for the amino acid lysine.
"So like AAA codes for the amino acid lysine. There's 64 of those, and if you change one, you get a new genetic code." (said at 0:17:20)
The canonical genetic code consists of 64 triplet codons composed of four nucleotide bases, which universally encode 20 canonical amino acids (with AAA specifically coding for lysine) and three stop signals. Changing codon assignments or reassigning codons generates altered genetic codes.
Genomically recoding an organism by altering codons can confer broad viral resistance, which has been experimentally achieved in E. coli.
"we have a project to change the genetic code to make any cell resistant to all viruses, and we just published a paper where we think we did that. The way that it works is that all viruses, as far as we know, depend on the host genetic code... so far we've only done it in one industrial organism, E. coli" (said at 0:16:10)
The claim is supported by experimental studies in synthetic biology. Genomically recoded Escherichia coli strains—engineered by replacing specific codons (such as all UAG stop codons) across the genome and eliminating the corresponding translation factors (such as release factor 1)—demonstrated broad resistance to infection across diverse bacteriophages (including λ, M13, P1, MS2, and T7) due to the phages' dependence on the standard host translational machinery.
Sponges can produce fiber-optic-like structures, and certain biological systems synthesize ferromagnetic materials used as internal compasses.
"they can make things that are fiber-optics-like in sponges, you can make semiconductors, ferromagnetic materials that help it like a compass, there are all kinds of dichroics and gratings that generate colors" (said at 0:10:50)
The claim is well-supported by scientific literature in biomineralization and microbiology:
1. Sponges, specifically glass sponges such as *Euplectella aspergillum* and *Hyalonema sieboldi*, produce biosilica spicules that function as biological optical fibers. These spicules feature a core-clad structure with varying refractive index profiles, enabling light transmission comparable to commercial glass optical fibers.
2. Biological systems, notably magnetotactic bacteria, synthesize nanoscale crystals of ferromagnetic iron minerals (such as magnetite or greigite) within specialized organelles called magnetosomes, which align to act as an intracellular magnetic compass for orientation along geomagnetic field lines.
Smallpox is completely extinct globally as a disease in nature.
"The only thing that is truly accessible equally that I can think of offhand is—and is a biotechnology—and that is smallpox. It's completely extinct, and so you don't have to constantly be bringing out a new drug or a new vaccine that maybe not everybody can afford" (said at 0:34:20)
Global eradication of smallpox (variola virus) was achieved following an intensive global vaccination campaign and was officially certified by the World Health Organization (WHO) at the 33rd World Health Assembly in May 1980. The last naturally occurring endemic case was recorded in Somalia in 1977. Because variola virus has no known non-human animal reservoirs, the disease is entirely extinct in nature, with remaining physical viral stocks strictly restricted to designated high-containment research repositories.
The first completely recoded organism genome was engineered primarily using single-stranded DNA-annealing proteins (SSAPs) and site-specific recombinases.
"And the other evidence of its power was that the first completely recoded genome was done mostly with a combination of SSAPs and recombinases, which is also very, very precise." (said at 0:39:15)
The first genomically recoded organism (Escherichia coli strain C321.ΔA, in which all 321 known UAG stop codons were replaced with UAA) was generated primarily using Multiplex Automated Genome Engineering (MAGE) paired with Conjugative Assembly Genome Engineering (CAGE). MAGE relies on single-stranded DNA-annealing proteins (SSAPs, specifically the bacteriophage λ Red Beta protein) to iteratively integrate synthetic oligonucleotides into the replicating chromosome, followed by recombinase-mediated and conjugative assembly methods to hierarchically combine recoded genomic segments into a single fully recoded organism.
- supports: Genome‐scale engineering for systems and synthetic biology (Molecular Systems Biology 2013) · cited 333x in the literature
"Recent advances have dramatically expanded our ability to engineer cells in a directed and combinatorial manner. Here, we review current technologies and methodologies for genome-scale engineering, discuss the prospects for extending efficient genome modification to new hosts, and explore the implications of continued advances toward the development of flexibly programmable chasses" (abstract, results, passage verified)
openalexfull study (doi) - supports: Large-scale recoding of a bacterial genome by iterative recombineering of synthetic DNA (Nucleic Acids Research 2017) · cited 72x in the literature
"The SIRCAS process involves direct iterative recombineering of 10-25 kb synthetic DNA constructs which are assembled in yeast and amplified by rolling circle amplification. Using SIRCAS, we create a Salmonella with 1557 synonymous leucine codon replacements across 176 genes, the largest number of cumulative recoding changes in a single bacterial strain to date. We demonstrate reproducibility over sixteen two-day cycles of integration and parallelization for hierarchical construction of a synthetic genome by conjugation. The resulting recoded strain grows at a similar rate to the wild-type strain and does not exhibit any major growth defects. This work is the first instance of synthetic bacterial recoding beyond the Escherichia coli genome" (abstract, results, passage verified)
openalexfull study (doi)
Most regulatory approved gene therapies work by gene addition rather than by gene editing.
"So most gene therapies that have been approved are adding genes, and this is done typically without CRISPR. When you have a genetic disease, you're missing a gene, so you don't really want to edit necessarily; you want to add it back in." (said at 0:42:03)
The claim is accurate. Historically and currently, the vast majority of regulatory-approved gene therapies (such as Luxturna, Zolgensma, Vyjuvek, Roctavian, Hemgenix, Kymriah, and Lovo-cel) work via gene addition (also referred to as gene augmentation or transgene delivery), typically using viral vectors (e.g., AAV, lentivirus) without genome editing tools like CRISPR. While gene editing therapies (such as exagamglogene autotemcel / Casgevy, approved in late 2023) have recently begun receiving regulatory approvals, gene addition remains the predominant paradigm among approved gene therapy products.
- supports: Evolving AAV-delivered therapeutics towards ultimate cures. (Journal of molecular medicine (Berlin, Germany) 2021) · cited 65x in the literature
"Since the first AAV-derived therapeutics Glybera was approved by the European Medicines Agency (EMA) in 2012, there is an increasing number of AAV-based gene augmentation therapies that have been developed and tested for treating incurable genetic diseases. In the subsequent years, the United States Food and Drug Administration (FDA) approved two additional AAV gene therapy products, Luxturna and Zolgensma, to be launched into the market." (abstract, passage verified)
pubmedfull study (doi) - supports: Advances in Gene Therapy for Inherited Haemoglobinopathies. (Hematology reports 2025) · cited 2x in the literature
"Lentiviral gene addition approaches have demonstrated durable expression of functional β-like globin transgenes... and, more recently, gene editing technologies such as CRISPR/Cas9 have enabled precise disruption of regulatory elements controlling γ-globin repression, leading to the approval of the first CRISPR-based therapy for SCD and β-thalassaemia." (abstract)
pubmedfull study (doi) - supports: The Journey of Gene Therapy in Sickle Cell Disease: How Molecular Advances Meet Clinical C… (Cells 2026)
"The approval of two autologous gene therapy products in 2023, exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel), marked a turning point for the SCD population and the gene therapy field in general. This review proposes a molecular rationale for fetal hemoglobin reactivation and β-globin gene addition, describes the engineering of lentiviral and CRISPR-based platforms" (abstract, passage verified)
pubmedfull study (doi)
Gene therapies and palliative care for rare genetic diseases typically cost millions of dollars per person over a lifetime, whereas preconception genetic carrier screening costs in the low hundreds of dollars.
"The use of gene therapy putting in a missing gene—and, in fact, editing for that matter—for rare genetic diseases is by its nature expensive. It's millions of dollars per person over a lifetime... But the preventative medicine in this case is low hundreds of dollars just to know yourself, to know how to keep your children healthy by making preconception choices." (said at 0:42:28)
Health economic evaluations and cost-of-care analyses consistently support this contrast. Approved gene therapies and lifetime management for severe rare genetic disorders (such as spinal muscular atrophy, dystrophic epidermolysis bullosa, and other Mendelian conditions) commonly incur list prices and lifetime direct costs in the millions of dollars per patient. In contrast, expanded preconception genetic carrier screening panels assessing hundreds of conditions typically cost in the low hundreds of dollars per individual/couple and have been demonstrated to be highly cost-effective or cost-saving relative to lifetime management costs.
- supports: Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen. (Genetics in medicine : official journal of the American College of Medical Genetics 2019) · cited 78x in the literature
"For every 100,000 pregnancies, 290 are predicted to be affected by ECS-panel conditions, which, on average, increase mortality by 26 undiscounted life-years and individually incur $1,100,000 in lifetime costs. Relative to minimal screening, preconception ECS reduces the affected birth rate and is estimated to be cost-effective" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa. (JAMA dermatology 2024) · cited 14x in the literature
"Estimated lifetime total costs per patient were $15 million (range, $10 million-$20 million) per patient with autosomal recessive DEB and $17 million (range, $11 million-$22 million) for patients with autosomal dominant DEB." (abstract, results, passage verified)
pubmedfull study (doi)
In the 1960s, a chimpanzee kidney transplant into a human patient survived and functioned for nine months.
"The idea of transplanting organs from animals to humans goes back at least to the 1960s, where a chimpanzee kidney survived for nine months in a schoolteacher who went back to teach and was normal for nine months." (said at 0:46:15)
Historical clinical records confirm that in 1963–1964, Dr. Keith Reemtsma and colleagues at Tulane University performed a series of chimpanzee-to-human kidney xenotransplants in 13 patients. One recipient, a 23-year-old schoolteacher, experienced stable graft function and returned to work for nearly nine months before dying suddenly from an electrolyte disturbance. Because this evidence comes from an uncontrolled historical case series, the certainty is rated as very low.
Non-human primates receiving germline gene-edited pig organ transplants have achieved survival times of approximately 500 to 600 days.
"synthetic biology that we do on the germline of pigs, which now made it into many preclinical primate transplant trials—pig to primate—and a few pig to human trials that are going on. Primate survival looks like around 600 days so far, and there's still a couple that are still alive at 500, 600 days." (said at 0:46:35)
Preclinical xenotransplantation studies using organs from genetically engineered porcine donors transplanted into non-human primates have demonstrated graft survival durations reaching and exceeding 500 to 600 days. For instance, baboons receiving cardiac xenografts from genetically modified pigs (with alpha 1-3 galactosyltransferase gene knockout and human transgenes) achieved graft survival up to 945 days with established prior benchmarks of 500 days. Similarly, kidney grafts from donor pigs carrying 69 genomic edits have supported long-term graft survival in cynomolgus monkeys. Because the supporting evidence comes exclusively from animal models, certainty is graded as very low.
- supports: Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD4… (Nature communications 2016) · cited 475x in the literature
"Here, we describe a reproducible, long-term survival of cardiac xenografts from alpha 1-3 galactosyltransferase gene knockout pigs, which express human complement regulatory protein CD46 and human thrombomodulin (GTKO.hCD46.hTBM), that were transplanted into baboons. ... Median (298 days) and longest (945 days) graft survival in five consecutive recipients using this regimen is significantly prolonged over our recently established survival benchmarks (180 and 500 days, respectively)." (abstract, passage verified)
pubmedfull study (doi) - supports: Design and testing of a humanized porcine donor for xenotransplantation. (Nature 2023) · cited 277x in the literature
"Here we describe the design, creation and long-term life-supporting function of kidney grafts from a genetically engineered porcine donor transplanted into a cynomolgus monkey model. The porcine donor was engineered to carry 69 genomic edits, eliminating glycan antigens, overexpressing human transgenes and inactivating porcine endogenous retroviruses." (abstract, passage verified)
pubmedfull study (doi)
Porcine endogenous retroviruses (PERVs) are present in the germline genome of all pigs and have been shown to infect and replicate in human cells in vitro.
"The viruses that we got rid of were endogenous retroviruses, meaning they're built into the pig genome of every pig on the planet. And they have been shown to infect human cells and to replicate and go into other human cells." (said at 0:50:03)
Porcine endogenous retroviruses (PERVs) are proviral DNA sequences integrated into the germline genome of all swine breeds. In vitro studies have established that infectious PERVs released from porcine cells can productively infect cultured human cells and undergo horizontal transmission (replication and secondary infection) between human cells, motivating gene-editing efforts (such as CRISPR-Cas9 inactivation) for pig-to-human xenotransplantation.
George Church and Luhan Yang's group published research demonstrating the use of CRISPR to target and eliminate African swine fever virus DNA.
"Anyway, as a side project, we published a paper on getting rid of African swine fever virus by making CRISPR to attack the viral DNA." (said at 0:50:45)
A 2024 study co-authored by Luhan Yang and George Church's team evaluated a multiplexed CRISPR-Cas9 system targeting nine loci across the African swine fever virus (ASFV) genome. The researchers demonstrated that targeting the viral DNA substantially suppressed ASFV replication in vitro and developed germline-edited pigs expressing the system, which delayed infection onset in some cases (though it did not ultimately confer complete survival upon challenge).
Humans who naturally carry homozygous null mutations in both copies of the PCSK9 gene are viable, healthy, and protected against cardiovascular disease.
"It was de-risked because there were a few humans that were walking around that were basically double-null for both copies of their PCSK9 from mom and dad, and that kind of showed us that it was going to be safe and effective." (said at 0:55:35)
Human genetic studies identified rare individuals carrying biallelic inactivating (loss-of-function) mutations in PCSK9 (compound heterozygotes or homozygotes) who have undetectable circulating PCSK9, extremely low circulating LDL cholesterol levels (e.g., ~14 mg/dL), and remain healthy and fertile without apparent adverse consequences. These natural human knockouts provided key biological evidence demonstrating that lifelong profound suppression of PCSK9 is viable, well-tolerated, and protective against coronary heart disease, directly validating PCSK9 as a safe therapeutic target.
- supports: Molecular characterization of loss-of-function mutations in PCSK9 and identification of a … (American journal of human genetics 2006) · cited 633x in the literature
"Mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9) that are associated with lower plasma levels of LDL-C confer protection from coronary heart disease... identified the first known individual who has no immunodetectable circulating PCSK9. This healthy, fertile college graduate, who was a compound heterozygote for two inactivating mutations in PCSK9, had a strikingly low plasma level of LDL-C (14 mg/dL). The very low plasma level of LDL-C and apparent good health of this individual demonstrate that PCSK9 plays a major role in determining plasma levels of LDL-C and provides an attractive target for LDL-lowering therapy." (abstract)
pubmedfull study (doi)
The maximum lifespan of mice is around 2 years, whereas bowhead whales can live up to approximately 200 years.
"The mice die at two years old, bowhead whales at 200, humans somewhere in between." (said at 0:55:17)
Comparative biology and mammalian longevity literature confirms that standard laboratory mice typically have an average lifespan of roughly 2 years (with maximum lifespans around 2 to 4 years depending on strain), whereas the bowhead whale (Balaena mysticetus) is recognized as the longest-lived mammal with an estimated maximum lifespan exceeding 200 years.
Expressing the four Yamanaka transcription factors (OSKM) can reprogram somatic cells, including skin cells from an 80-year-old human, back to an embryonic-like pluripotent stem cell state capable of forming almost all body tissues.
"These are DNA-binding proteins that regulate the expression of genes, four of them, so-called Yamanaka factors, or OSKM as an abbreviation. These will very convincingly take a very old cell and turn it into a very young cell, meaning like, say, a skin cell from an 80-year-old, and it will take on many of the characteristics, most of the significant characteristics of an embryonic cell in that it can produce almost all the tissues of the body" (said at 0:57:50)
The expression of the four Yamanaka transcription factors (Oct3/4, Sox2, Klf4, and c-Myc; OSKM) successfully reprograms adult somatic cells, including dermal fibroblasts from elderly and centenarian donors, into induced pluripotent stem cells (iPSCs). These reprogrammed cells exhibit characteristics indistinguishable from human embryonic stem cells, including telomere rejuvenation, embryonic gene expression profiles, and pluripotency (the capacity to differentiate into cell types representing all three germ layers).
- supports: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. (Cell 2007) · cited 20307x in the literature
"Here, we demonstrate the generation of iPS cells from adult human dermal fibroblasts with the same four factors: Oct3/4, Sox2, Klf4, and c-Myc. Human iPS cells were similar to human embryonic stem (ES) cells in morphology, proliferation, surface antigens, gene expression, epigenetic status of pluripotent cell-specific genes, and telomerase activity. Furthermore, these cells could differentiate into cell types of the three germ layers in vitro and in teratomas." (abstract, passage verified)
pubmedfull study (doi) - supports: Rejuvenating senescent and centenarian human cells by reprogramming through the pluripoten… (Genes & development 2011) · cited 569x in the literature
"Thus, we show that our iPSCs generated from senescent and centenarian cells have reset telomere size, gene expression profiles, oxidative stress, and mitochondrial metabolism, and are indistinguishable from hESCs. Finally, we show that senescent and centenarian-derived pluripotent stem cells are able to redifferentiate into fully rejuvenated cells." (abstract, passage verified)
pubmedfull study (doi)
Heterochronic parabiosis and blood exchange studies show that blood from older animals induces aging biomarkers in younger animals, while blood from young animals rejuvenates older animals across multiple physiological markers.
"It's shown that what's in the blood of older and younger animals can influence one another. The older blood makes the younger ones old, and the young blood makes the older animals younger by a variety of biomarkers and disease-related things." (said at 0:58:50)
Animal studies utilizing heterochronic parabiosis (surgically connecting the circulations of young and old animals) and heterochronic blood exchange show bidirectional systemic influences on aging phenotypes. Exposure to young blood or serum restores regenerative capacity and cellular signaling in aged tissues, such as skeletal muscle satellite cells and hepatic progenitor cells. Conversely, transfusing aged blood into young animals rapidly induces cellular senescence, impairs neurogenesis, and suppresses tissue repair across multiple organ systems. Because these findings derive exclusively from preclinical animal models, certainty is graded as very low.
- supports: Rejuvenation of aged progenitor cells by exposure to a young systemic environment. (Nature 2005) · cited 2297x in the literature
"Notably, heterochronic parabiosis restored the activation of Notch signalling as well as the proliferation and regenerative capacity of aged satellite cells... Furthermore, heterochronic parabiosis increased aged hepatocyte proliferation and restored the cEBP-alpha complex to levels seen in young animals." (abstract, results)
pubmedfull study (doi) - supports: A single heterochronic blood exchange reveals rapid inhibition of multiple tissues by old … (Nature communications 2016) · cited 304x in the literature
"Heterochronic parabiosis rejuvenates the performance of old tissue stem cells at some expense to the young, but whether this is through shared circulation or shared organs is unclear." (abstract, background, passage verified)
pubmedfull study (doi) - supports: Systemic induction of senescence in young mice after single heterochronic blood exchange. (Nature metabolism 2022) · cited 112x in the literature
"Here, using heterochronic blood exchange in male mice, we show that aged mouse blood induces cell and tissue senescence in young animals after one single exchange." (abstract, results, passage verified)
pubmedfull study (doi)
COVID-19 morbidity, mortality, and associated cognitive consequences increase steeply in individuals around age 60.
"even like accidental death, infectious diseases like COVID has a very—and its cognitive consequences have very steep increases at around 60 years old." (said at 1:00:55)
Large-scale epidemiological studies and meta-analyses show that COVID-19 morbidity and mortality exhibit a strong exponential relationship with age. Risk increases sharply beginning around ages 55 to 65. For example, a systematic review and meta-analysis of age-specific infection fatality rates (IFRs) demonstrated that while the estimated IFR was very low in younger populations (0.01% at age 25), it rose steeply to 0.4% by age 55, 1.4% at age 65, 4.6% at age 75, and 15% at age 85.
George Church's lab conducted an AAV gene therapy study in mice delivering soluble factors TGF-beta receptor, FGF21, and alpha-Klotho to reverse aging-related phenotypes.
"HOST: So I recall like one of your former publications, I forgot what year, I think it was the PNAS one, where you did gene therapy and added three transcription factors to rodents, to mice, and there was some reversal of aging or biomarkers. And it was like TGF-beta receptor and FGF21 and alpha-Klotho? GUEST1: Yeah, those three, yeah. Those were not transcription factors; those were soluble factors." (said at 1:01:01)
The claim accurately reflects a 2019 PNAS study led by Noah Davidsohn and George M. Church. The researchers delivered three protective soluble factors—fibroblast growth factor 21 (FGF21), α-Klotho, and soluble transforming growth factor-β receptor 2 (sTGFβR2)—via adeno-associated viral (AAV) vectors in mouse models, successfully treating and reversing phenotypes of multiple age-related diseases including heart failure, renal atrophy, obesity, and type 2 diabetes. Because the findings are currently limited to preclinical animal models, certainty for human application is very low.
Researchers demonstrated that delivering three Yamanaka transcription factors (Oct4, Sox2, and Klf4; OSK) via adeno-associated virus (AAV) can induce cellular rejuvenation in mouse models.
"But we also did a separate experiment where we took three transcription factors, O, S, and K of OSKM—separate experiments, but delivered in similar ways, adeno-associated virus." (said at 1:01:30)
In a 2020 study published in Nature (Lu et al.), researchers demonstrated that delivering Oct4, Sox2, and Klf4 (OSK) via an adeno-associated virus (AAV) vector into mouse retinal ganglion cells restored youthful DNA methylation patterns and transcriptomes, promoted axon regeneration after optic nerve injury, and reversed vision loss in aged mice. Because the evidence is derived exclusively from preclinical animal models, certainty is rated as very low.
George Church's group engineered pig germlines with 42 to 62 simultaneous genome edits targeting porcine endogenous retroviruses and immunological genes for xenotransplantation.
"So our previous record of 62—or 42, depending on how you count it—was in pigs, and it was for tissue engineering; it was germline." (said at 0:45:55)
The claim accurately reflects published research from George Church's laboratory and collaborators. The team established multiplex CRISPR-Cas9 genome engineering in swine cells, initially demonstrating the simultaneous inactivation of 62 copies of porcine endogenous retroviruses (PERVs) to address microbiological safety hurdles for xenotransplantation tissue engineering, and later engineering pigs carrying dozens of simultaneous edits combining PERV knockouts and immunological compatibility genes.
Alpha-Klotho and FGF21 are natural soluble factors, whereas the TGF-beta receptor is naturally membrane-bound and required engineering into a soluble form for systemic delivery.
"the other two are natural, alpha-Klotho and FGF21. But the TGF-beta receptor is normally membrane-bound; we made a soluble form of it. So all three of them tend to be soluble" (said at 1:02:26)
The speaker's statement accurately describes the biological characteristics of these three proteins and the engineering approach used in their published gene therapy study. Fibroblast growth factor 21 (FGF21) and αKlotho exist naturally in circulating, soluble forms. In contrast, transforming growth factor-β receptor 2 (TGFβR2) is a transmembrane cell-surface receptor; to target TGF-β signaling systemically via adeno-associated virus (AAV) gene therapy, the authors engineered a gene construct encoding a soluble extracellular domain form of the receptor (sTGFβR2). This combination gene therapy approach utilizing FGF21, αKlotho, and sTGFβR2 was demonstrated in mice by Davidsohn et al. (PNAS, 2019).
Church's research group evaluated 45 different single gene therapies in rodents to select the subset of three factors for combination therapy.
"we did 45 different gene therapies singly, one at a time, in rodents, mice, to find the subset of three that we wanted to test in rodents in combinations, various combinations." (said at 1:05:28)
The speaker's description matches the research program from George Church's laboratory (led by Noah Davidsohn and colleagues), which screened candidate longevity-associated genes in mouse models before publishing on the combination of three specific factors (FGF21, αKlotho, and sTGFβR2) delivered via adeno-associated virus (AAV) to treat multiple age-related diseases. Because the underlying evidence consists of preclinical animal models and internal laboratory screening assays, the certainty is graded as very low.
There is a regulatory restriction prohibiting human embryos from being cultured in vitro past 14 days of development.
"there's a ban on letting human embryos develop past 14 days in a dish" (said at 1:07:33)
The "14-day rule" is an established regulatory and bioethical policy that limits the in vitro culture of intact human embryos to a maximum of 14 days of development (or the formation of the primitive streak). While international professional guidelines (such as the 2021 update from the International Society for Stem Cell Research) have recently revisited the blanket prohibition to suggest case-by-case review, statutory and regulatory bans limiting embryo culture to 14 days remain codified in law across numerous jurisdictions worldwide.
Individuals who are homozygous for the APOE4 allele have approximately a 20-fold increased risk of developing Alzheimer's disease.
"APOE4, which if you're homozygous you have like a 20-fold increased risk for Alzheimer's, to APOE3, right?" (said at 1:09:45)
A landmark meta-analysis of 5,930 Alzheimer's disease (AD) cases and 8,607 controls across multiple populations established that homozygous APOE ε4/ε4 status confers a substantial increase in AD risk relative to the common ε3/ε3 genotype. Specifically, the odds ratio (OR) for developing AD among Caucasian ε4/ε4 homozygotes was 14.9 (95% CI, 10.8–20.6), and in Japanese populations reached 33.1 (95% CI, 13.6–80.5). The statement that APOE4 homozygosity carries approximately a 20-fold increased risk aligns well with the published epidemiologic effect sizes.
- supports: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype an… (JAMA ) · cited 4677x in the literature
"Among Caucasian subjects from clinic- or autopsy-based studies, the risk of AD was significantly increased for people with genotypes epsilon2/epsilon4 (OR=2.6, 95% CI=1.6-4.0), epsilon3/epsilon4 (OR=3.2, 95% CI=2.8-3.8), and epsilon4/epsilon4 (OR=14.9, 95% CI= 10.8-20.6)... The APOE epsilon4-AD association in Japanese subjects was stronger than in Caucasian subjects (epsilon3/epsilon4: OR=5.6, 95% CI=3.9-8.0; epsilon4/epsilon4: OR=33.1, 95% CI=13.6-80.5)." (abstract, results, passage verified)
pubmed
Louise Brown was the first baby born who was conceived via in vitro fertilization in 1978.
"in 1978 the first—was it Louise Brown was the was the first baby born was conceived by in vitro fertilization, and considered one of the biggest medical breakthroughs of the 20th century." (said at 1:15:52)
Louise Brown was the world's first child born via in vitro fertilization (IVF) and embryo transfer in England in July 1978, following the pioneering work of Robert Edwards and Patrick Steptoe.
Approximately 6 million babies have been born globally through in vitro fertilization.
"I think 6 million babies have been born that way, including some of my close colleagues." (said at 1:22:02)
The speaker's estimate of approximately 6 million babies born globally through in vitro fertilization (IVF) and assisted reproductive technology (ART) reflects standard global surveillance and registry estimates. The International Committee for Monitoring Assisted Reproductive Technologies (ICMART) and related global reviews estimated cumulative ART births passed 5 million around 2013, reached 6 to 8 million in subsequent years, and recent published estimates indicate the cumulative total now exceeds 8 to 10 million worldwide.
Top adenoviral-vectored COVID-19 vaccines cost as little as $2 per dose, compared to typical gene therapies that cost around $2 million.
"The latest round of vaccines are kind of in a format of gene therapy and are very inexpensive compared to most gene therapies that are typically $2 million. In the case of COVID-19, they were as little as $2 for an adenoviral capsid around the double-stranded DNA for three of the top five vaccines." (said at 1:29:20)
The speaker's comparison of costs between adenoviral-vectored COVID-19 vaccines and commercial gene therapies is broadly supported by health economics literature and pharmaceutical pricing data. Recombinant adenoviral-vector platforms (delivering double-stranded DNA encoding the viral antigen in an adenoviral capsid, such as Oxford/AstraZeneca's ChAdOx1-S) were manufactured at massive scale and distributed under not-for-profit or advance-market agreements for roughly $2 to $4 per dose in several markets. In contrast, approved in vivo and ex vivo cell and gene therapies (such as those for rare genetic conditions and hemoglobinopathies) typically carry wholesale acquisition prices between $1 million and $3 million per treatment course (frequently modeled at a standard $2 million benchmark).
He Jiankui targeted the CCR5 gene to confer HIV resistance in the gene-edited human embryos.
"I think was actually a pretty good choice of CCR5 and HIV resistance in He Jiankui's case." (said at 1:16:40)
The scientific literature confirms that the CCR5 gene plays a central role in HIV entry, and individuals homozygous for CCR5 loss-of-function variants (such as CCR5-Δ32) exhibit near-complete resistance to HIV infection. In 2018, researcher He Jiankui performed the first reported human germline genome editing using CRISPR to target the CCR5 gene in human embryos with the stated goal of conferring HIV resistance.
Preconception genetic screening and mate-selection programs in specific populations have virtually eliminated certain severe inherited genetic diseases.
"So there's a tiny sector of society that practices preconception decision-making, and those have almost eliminated major, serious genetic diseases." (said at 1:30:27)
Preconception carrier screening and mate-selection programs (most notably Dor Yeshorim and community screening programs within Ashkenazi Jewish populations) have achieved near-elimination of severe recessive disorders such as Tay-Sachs disease within those participating communities. Published literature frequently highlights the Jewish community's population-based carrier screening as a successful paradigm demonstrating the prevention of severe Mendelian genetic diseases through preconception decision-making.
CCR5 knockout or null mutations can increase susceptibility to West Nile virus and certain influenza strains.
"So people will say, "Well, CCR5 is not a good idea for germline, and maybe it's not even a good idea for somatic because it could make you sensitive to West Nile or to certain influenza."" (said at 1:37:15)
Human genetic association studies and meta-analyses support that CCR5 deficiency (such as the CCR5-Δ32 null variant or knockout) is associated with an increased risk of severe, symptomatic West Nile virus disease and increased severity/mortality in certain influenza infections. A systematic review and meta-analysis confirmed that CCR5 variation is significantly associated with symptomatic West Nile virus disease (meta-OR = 1.29), and observational studies have linked CCR5-Δ32 with increased early/late clinical manifestations of West Nile virus as well as higher mortality during severe influenza infection.
- supports: CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infe… (The Journal of infectious diseases 2010) · cited 135x in the literature
"CCR5 deficiency is not a risk factor for WNV infection per se, but it is a risk factor for both early and late clinical manifestations after infection. Thus, CCR5 may function normally to limit disease due to WNV infection in humans." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: CCR5 deficiency predisposes to fatal outcome in influenza virus infection. (The Journal of general virology 2015) · cited 68x in the literature
"CCR5-Δ32 patients (17.4%) showed a higher mortality rate than WT individuals (4.7%; P = 0.021), which indicates that CCR5-Δ32 patients are at higher risk than the normal population of a fatal outcome in influenza infection." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Identification of genetic variants associated with dengue or West Nile virus disease: a sy… (BMC infectious diseases 2018) · cited 43x in the literature
"In particular we found variation within the OAS1 (meta-OR = 0.83, 95% CI: 0.69-1.00) and CCR5 (meta-OR = 1.29, 95% CI: 1.08-1.53) genes is significantly associated with West Nile virus disease" (abstract, results, passage verified)
pubmedfull study (doi)
Mosquitofish do not depend on mosquitoes as an obligatory food source.
"Um, but, uh, even mosquitofish do not depend on mosquitoes." (said at 1:43:24)
The claim is supported by dietary studies of mosquitofish (Gambusia affinis and Gambusia holbrooki). Mosquitofish are generalist and opportunistic omnivores whose diet varies widely according to local prey availability, consisting of microcrustaceans (such as cladocerans and copepods), terrestrial insects, detritus, aquatic bugs, and other small invertebrates. They do not rely obligatorily on mosquito larvae or adults for survival.
A Lyme disease vaccine has remained in continuous veterinary use for dogs after the human vaccine was withdrawn.
"It's been in use in dogs several the whole time. It's it's one of these cases where dogs get better medical care than humans do, because, you know, we love our dogs and apparently we don't care about ourselves." (said at 1:47:25)
The claim is supported by veterinary and medical literature. Following the withdrawal of the only licensed human Lyme disease vaccine (LYMErix) in the early 2000s due to safety controversies and declining demand, canine Lyme disease vaccines (including whole-cell bacterins and recombinant outer surface protein formulations) have remained continuously available and approved for veterinary use in dogs.
Eating a meal promotes sleepiness in many individuals.
"the tendency to go to sleep after a meal, which is true for many people, it's especially true for me" (said at 1:50:20)
Postprandial somnolence (sleepiness after eating) is a well-documented physiological response. Controlled trials comparing meal ingestion to sham feeding have confirmed that eating a solid meal significantly reduces objective sleep onset latency (the time it takes to fall asleep). Multiple physiological factors, including meal composition, gastrointestinal signaling, and inflammatory cytokines (such as IL-1), contribute to post-meal fatigue and sleepiness.
Only female mosquitoes bite and consume blood, whereas male mosquitoes feed on nectar and act as pollinators.
"The males are pollinators, uh, females, um, are the bloodsuckers in this case." (said at 1:42:18)
Entomological research confirms that female mosquitoes require blood meals for egg production (hematophagy), whereas male mosquitoes lack mouthparts capable of piercing skin and feed exclusively on plant nectar, honeydew, and other sugar sources. While foraging on floral nectar, male (as well as female) mosquitoes visit flowers and can serve as pollinators for various plant species.
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.